Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton Sells 3,798 Shares

Posted by Defense World Staff on Mar 15th, 2023

Cryoport, Inc. (NASDAQ:CYRX – Get Rating) CEO Jerrell Shelton sold 3,798 shares of the company’s stock in a transaction that occurred on Monday, March 13th. The stock was sold at an average price of $20.14, for a total transaction of $76,491.72. Following the completion of the transaction, the chief executive officer now owns 435,588 shares of the company’s stock, valued at $8,772,742.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Cryoport Price Performance

CYRX stock opened at $21.51 on Wednesday. Cryoport, Inc. has a one year low of $15.63 and a one year high of $45.36. The company’s fifty day moving average price is $21.56 and its 200-day moving average price is $22.82. The company has a debt-to-equity ratio of 0.76, a quick ratio of 14.11 and a current ratio of 14.79. The company has a market capitalization of $1.04 billion, a PE ratio of -23.21 and a beta of 1.34.

Cryoport (NASDAQ:CYRX – Get Rating) last released its quarterly earnings results on Thursday, February 23rd. The consumer goods maker reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.03). The business had revenue of $60.36 million for the quarter, compared to analysts’ expectations of $58.26 million. Cryoport had a negative net margin of 15.73% and a negative return on equity of 6.18%. Cryoport’s revenue for the quarter was up 6.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.32) EPS. On average, equities analysts anticipate that Cryoport, Inc. will post -0.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Cryoport

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. increased its position in Cryoport by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,515,305 shares of the consumer goods maker’s stock valued at $122,720,000 after acquiring an additional 159,133 shares during the last quarter. Invesco Ltd. increased its position in Cryoport by 17.7% during the first quarter. Invesco Ltd. now owns 3,228,313 shares of the consumer goods maker’s stock valued at $112,700,000 after acquiring an additional 485,972 shares during the last quarter. BlackRock Inc. increased its position in Cryoport by 2.0% during the first quarter. BlackRock Inc. now owns 3,028,269 shares of the consumer goods maker’s stock valued at $105,718,000 after acquiring an additional 59,877 shares during the last quarter. Impax Asset Management Group plc increased its position in Cryoport by 46.7% during the fourth quarter. Impax Asset Management Group plc now owns 2,484,660 shares of the consumer goods maker’s stock valued at $42,784,000 after acquiring an additional 791,037 shares during the last quarter. Finally, Macquarie Group Ltd. increased its position in Cryoport by 5.7% during the second quarter. Macquarie Group Ltd. now owns 1,820,480 shares of the consumer goods maker’s stock valued at $56,398,000 after acquiring an additional 97,728 shares during the last quarter. Hedge funds and other institutional investors own 88.66% of the company’s stock.

Wall Street Analyst Weigh In

CYRX has been the subject of a number of recent analyst reports. KeyCorp dropped their price target on shares of Cryoport from $40.00 to $30.00 and set an “overweight” rating for the company in a research report on Thursday, December 8th. B. Riley dropped their price target on shares of Cryoport from $55.00 to $30.00 and set a “buy” rating for the company in a research report on Wednesday, November 16th. Finally, Needham & Company LLC boosted their target price on shares of Cryoport from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, February 24th.

About Cryoport

(Get Rating)

CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.